Abpro Holdings, Inc. is a biotechnology company developing next-generation antibody therapeutics for immuno-oncology and ophthalmology. Its lead candidates, ABP-102 and ABP-201, use a proprietary TetraBi antibody format. ABP-102 targets HER2 and CD3 for HER2+ solid tumors; ABP-201 co-targets VEGF and ANG-2 for wet age-related macular degeneration. The company leverages its DiversImmune and MultiMab platforms and has partnerships with Celltrion and Abpro Bio International.
expected 2026-12-01
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-04-15 | 2024-12-31 | 0001213900-25-032133 | EDGAR | 103K words |
| 2024-03-29 | 2023-12-31 | 0001193125-24-081194 | EDGAR | 75K words |
| 2023-04-03 | 2022-12-31 | 0001193125-23-088454 | EDGAR | — |
| 2022-03-25 | 2021-12-31 | 0001193125-22-084159 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001213900-26-090028 | EDGAR | 26K words |
| 2025-11-14 | 2025-09-30 | 0001213900-25-110972 | EDGAR | 35K words |
| 2025-08-13 | 2025-06-30 | 0001213900-25-075691 | EDGAR | 33K words |
| 2025-05-15 | 2025-03-31 | 0001213900-25-044318 | EDGAR | 29K words |
| 2024-11-26 | 2024-09-30 | 0001213900-24-102370 | EDGAR | 27K words |
| 2024-08-23 | 2024-06-30 | 0001193125-24-206165 | EDGAR | 24K words |
| 2024-07-09 | 2024-03-31 | 0001193125-24-176812 | EDGAR | 22K words |
| 2023-12-15 | 2023-09-30 | 0001193125-23-296620 | EDGAR | 22K words |
| 2023-08-22 | 2023-06-30 | 0001193125-23-218080 | EDGAR | — |
| 2023-05-22 | 2023-03-31 | 0001193125-23-150482 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001193125-22-282585 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001193125-22-217578 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-01 | 0001213900-26-095822 | EDGAR | 1K words |
| 2026-08-25 | 0001213900-26-093599 | EDGAR | 1K words |
| 2026-02-20 | 0001213900-26-018819 | EDGAR | 1K words |
| 2026-02-11 | 0001213900-26-014903 | EDGAR | 2K words |
| 2026-02-03 | 0001213900-26-011462 | EDGAR | 1K words |
| 2026-01-23 | 0001213900-26-007215 | EDGAR | 1K words |
| 2026-01-06 | 0001213900-26-001570 | EDGAR | 1K words |
| 2025-12-15 | 0001213900-25-121446 | EDGAR | 1K words |
| 2025-12-09 | 0001213900-25-119439 | EDGAR | 1K words |
| 2025-11-04 | 0001213900-25-105590 | EDGAR | 2K words |
102 total filings indexed. 76 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001893219 |
| Ticker | ABPO |
| Exchange | OTC |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ABPO (~200 tokens, structured JSON with cryptographic provenance)